Dr. Caimi
December 15, 2023/Cancer/Research

CAR-T Cell Therapy Effective in Refractory Double-Hit/Triple-Hit Lymphoma

Two thirds of patients responded to CAR T-cell therapy

Relapsed refractory multiple myeloma treatment
December 12, 2023/Cancer/Research

Teclistamab Appears Safe and Effective in Real-World Patients with Relapsed/Refractory Multiple Myeloma

Despite sicker patients, response rates of teclistamab in a real-world study were similar to those from a pivotal clinical trial

23-CNR-4419109-CQD-Hero-650×450 Dr Sauter
December 11, 2023/Cancer/Research

Cell Therapy Offers New Hope for Refractory/Relapsed AML

Investigational chimeric antigen receptor natural killer cell therapy NKX101 associated with promising early response in patients with relapsed/refractory acute myeloid leukemia


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

23-CNR-4384100-CQD-650×450 Dr Halle Moore
December 8, 2023/Cancer/Research

Fertility and Pregnancy in Young Patients with Breast Cancer

San Antonio Breast Cancer Symposium presentations underscore safety of assisted reproductive technology and pregnancy in women during and after breast cancer treatment

23-CNR-4198921-CQD-Hero-650×450 Dr Cho 2
December 6, 2023/Cancer/Research

Mathematical Model Provides Further Insight on Spatially Fractionated Radiotherapy

Study offers a foundation for additional research to examine radiation and immune response

23-CNR-4259358-CQD-Hero-Dr Hamilton 650×450
November 28, 2023/Cancer/Research

Study Demonstrates Fewer Toxicities and Faster Engraftment with Reduced-Dose Methotrexate for Preventing Graft-Versus-Host Disease

Researchers compared tacrolimus/methotrexate to tacrolimus and reduced-dose methotrexate/mycophenolate

23-CNR-4343632-CQD-Hero-650×450 Dr Shah
November 7, 2023/Cancer/Research

Low-Dose Radiation Therapy Reemerging for Osteoarthritis

Cleveland Clinic radiation oncologists aim to bring the noninvasive approach back to the U.S., where use has declined

October 23, 2023/Cancer/Research

p53-Independent Non-Cytotoxic Therapy May be a Viable Option for Chemotherapy-Resistant Small Cell Lung Cancer

Targeting DNMT1 shows promise in chemotherapy- and immunotherapy-resistant SCLC

23-CNR-4044609-CQD-Hero-650×450 AML study
October 20, 2023/Cancer/Research

The Role of Immune Escape in Post-Transplant Leukemia Relapse

Immunological pressure driving genetic mutations

BackPage 2 of 42Next